Clinical trials: Patients With Chronic Migraine
Migraine
The MOTS (Medication Overuse Treatment Strategy) Trial
There are two commonly used treatment strategies for treating patients who have chronic migraine with medication overuse. This study will compare the outcomes amongst patients randomized to one of the two treatment strategies.
- Trial name
- MOTS (NCT02764320)
- Testing
- Migraine Prophylactic Therapy Only, Discontinuation of Overused Medication
- Where
- 29 sites in United States
- Volunteers
- 720 people
- Sponsor
- Mayo Clinic
Headache Migraine Chronic
Spectacle Tints and Thin-Films for Migraine
Nearly all migraine sufferers report sensitivity to light during a headache and a significant proportion of sufferers report light sensitivity between attacks. Light is also a common trigger for migraine headaches.
- Trial name
- NCT02720211
- Testing
- Gray tinted spectacle lenses, Thin-Film spectacle lenses
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Utah
Chronic Migraine, Headaches
A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
- Trial name
- NCT01749410
- Testing
- onabotulinumtoxinA
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Allergan
Migraine Disorders
An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
This is an observational study to describe the long term use of Onabotulinumtoxin A (BOTOX®) as prescribed by the physician for headache prophylaxis in adults with chronic migraine. All treatment decisions lie with the physician.
- Trial name
- NCT01686581
- Testing
- botulinum toxin Type A
- Where
- 77 sites in Germany, Italy and 5 more
- Volunteers
- 641 people
- Sponsor
- Allergan
Migraine Disorders
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- PROMISE 2 (NCT02974153)
- Testing
- ALD403 (Eptinezumab)
- Where
- 144 sites in United States, Belgium and 11 more
- Volunteers
- 1,121 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine Disorder
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine
- Trial name
- PREVAIL (NCT02985398)
- Testing
- ALD403 (Eptinezumab)
- Where
- 20 sites in United States
- Volunteers
- 128 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine Headache
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)
This study consists of a 4-week screening period, a 24-week treatment period for all participants, followed by a 28-week treatment period extension (to 52 weeks in total) for a subset of at least 60 and up to 80 participants, and…
- Trial name
- NCT03557333
- Testing
- INP104
- Where
- 36 sites in United States
- Volunteers
- 360 people
- Sponsor
- Impel Pharmaceuticals
Migraine
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could…
- Trial name
- HER-MES (NCT03828539)
- Testing
- Erenumab, Topiramate
- Where
- 79 sites in Germany
- Volunteers
- 777 people
- Sponsor
- Novartis Pharmaceuticals
Migraine Disorders
BOTOX® Prophylaxis in Patients With Chronic Migraine
This is a post authorization observational study to monitor the utilization practices and describe the safety profile of BOTOX® in clinical practice for the prophylactic treatment of headaches in adult patients with chronic…
- Trial name
- NCT01432379
- Testing
- botulinum toxin Type A
- Where
- 4 sites in Germany, Spain and 2 more
- Volunteers
- 1,168 people
- Sponsor
- Allergan
Chronic Migraine
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
- Trial name
- REGAIN (NCT02614261)
- Testing
- Galcanezumab
- Where
- 117 sites in United States, Argentina and 11 more
- Volunteers
- 1,117 people
- Sponsor
- Eli Lilly and Company
Chronic Migraine
Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA (BOTOX®) in adults with chronic migraine.
- Trial name
- NCT01833130
- Testing
- OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Allergan
Migraine Disorders
A Multicenter Assessment of ALD403 in Chronic Migraine
The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- NCT02275117
- Testing
- ALD403
- Where
- 92 sites in United States, Australia and 2 more
- Volunteers
- 665 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
- Trial name
- NCT04825678
- Testing
- Erenumab
- Where
- 42 sites in United States
- Volunteers
- 240 people
- Sponsor
- Amgen
Chronic Migraine, Chronic Migraine, Headache
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
This is a phase 2, double-blind, randomized, multicenter, placebo-controlled, three arm parallel study to evaluate the efficacy and safety of two different dosages (30 IU daily and 60 IU daily) of TNX-1900 in patients with…
- Conditions
- Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine
- Trial name
- PREVENTION (NCT05679908)
- Testing
- TNX-1900
- Where
- 26 sites in United States
- Volunteers
- 88 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Migraine Disorders
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
This open-label study will assess the long-term efficacy, safety, and tolerability of onabotulinumtoxinA administered for prophylaxis of headaches in patients with chronic migraine.
- Trial name
- NCT01516892
- Testing
- onabotulinumtoxinA
- Where
- 32 sites in United States, Australia and 1 more
- Volunteers
- 716 people
- Sponsor
- Allergan